CentoCancer™ - Strive for the Most Complete Information
CentoCancer™ - The Specially Designed Cancer-Risk-Related Panel, Created for all Patients With a Positive Family History of Cancer.
The correct profiling of mutations in cancer genes represents a fundamental step in the diagnosis and
treatment of these malignancies. Certain mutations result in increased risk for hereditary cancer, and lead to development of breast, ovarian, colon, gastric, renal or other cancers.
CENTOGENE now offers CentoCancer™ - a specific and sensitive panel with highly penetrant cancer genes. With this panel we would like to offer you a complete answer to achieve the best possible
therapeutic approach for your patients.
CentoCancer™ identifies an elevated risk of significant hereditary cancers
CENTOGENE´s CentoCancer™ is a 31-gene panel that identifies an elevated risk of significant hereditary cancers, including breast, ovarian, gastric, colon, endometrial, prostate, pancreatic, renal, liver, and skin cancer.
CentoCancer™ addresses people with an identified cancer where the type of cancer or the family history warrant an extended NGS panel analysis, or those who have no family history, no positive anamnesis and would like to know their risk of inherited cancer.
CentoCancer™ includes the most relevant genes: APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, and TP53.
Each gene in CentoCancer™ has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal, and prostate cancer.
Who should consider CentoCancer™ for genetic testing?
- Affected individuals with an increased risk of hereditary cancer indicated by family history, multifocal
tumor development, or early onset.
- Non-affected individuals with a positive family history.
Increased risk of hereditary cancers
Carriers of inherited pathogenic variants in some cancer associated genes have an increased risk of
developing tumors in other tissues. The affected tissues and the lifetime risk of developing cancer in these tissues is dependent on the affected gene. For pathogenic variants in BRCA1, the risk of developing breast cancer is estimated to be 51% up to age 50 and 87% to age 80. In addition, BRCA1 carriers have a 23% increased risk of developing ovarian cancer by age 50 and a 44% risk by age 80. There is also an
increased risk of pancreatic cancer, and male carriers have an increased risk of breast and prostate cancer. In comparison, carriers of pathogenic STK11 variants have a 45-50% risk of breast cancer and 18-21% of ovarian cancer until the age of 80, but additionally also have an increased risk of colorectal, gastric,
endometrial, small bowel, testicular cervical, and lung cancers. The identification of a pathogenic variant in a specific gene can therefore be associated with a risk of cancer of other tissues which may not be
noticed, and surveillance and treatment programs should also be tailored with regard to an affected cancer gene.
Early detection of hereditary cancer significantly prolongs survival and offers many opportunities for early treatment or management. In addition to the cancer prevention programs generally recommended, people with an increased risk due to inherited mutations in cancer genes should be offered additional programs
according to guidelines regarding the risks for breast and other tumors.
Patients with a significantly increased cancer risk due to an inherited variant should be informed about the possibilities of individual risk reduction. Toxic substances should be avoided and an optimal therapeutic
approach, including possible surgical preventive measures, can be discussed.